(Q43172783)

English

Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).

scientific article published in November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lopinavir/ritonavir

1 reference

based on heuristic

inferred from title

author name string

Estevão P Nunes

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Marilia Santini de Oliveira

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Monica Merçon

3

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Roberto Zajdenverg

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Jose Claudio Faulhaber

5

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

José Henrique Pilotto

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Jorge Eurico Ribeiro

7

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Michael Norton

8

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Mauro Schechter

9

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

publication date

1 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

368-374

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

Limited Penetration of Lopinavir and Ritonavir in the Genital Tract of Men Infected with HIV-1 in Brazil

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-368

21 January 2018

Identifiers

10.1310/HCT1006-368

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43172783&oldid=1600686163"